Overview

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2025-08-18

Target enrollment:

Participant gender:

Summary

The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company
Loxo Oncology, Inc.

Collaborators:

Eli Lilly and Company
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Treatments:

Carboplatin
Cisplatin
Pembrolizumab
Pemetrexed